Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer.
OBJECTIVE
Although Helicobacter pylori (H. pylori) eradication has been shown to inhibit gastric cancer, it does not completely suppress it. Therefore, risk factors of gastric cancer development following H. pylori eradication were examined.


METHODS
A total of 2355 patients (1501 males and 824 females) underwent successful eradication of H. pylori. Endoscopic atrophy, histological gastritis, atrophy, intestinal metaplasia (IM), and operative link for gastritis assessment (OLGA) staging were subsequently evaluated.


RESULTS
Following eradication, 33/2355 patients (25 males and 8 females) developed gastric cancer. Compared to a nongastric cancer group that was matched according to gender and age, the incidence of endoscopic atrophy (3.52 ± 1.45 vs. 4.85 ± 1.18, p < 0.001), histological atrophy at the greater curvature of the antrum (1.42 ± 0.80 vs. 1.95 ± 0.86, p = 0.0059), inflammation (2.05 ± 0.59 vs. 2.33 ± 0.66, p = 0.031), IM at the greater curvature of the corpus (0.06 ± 0.30 vs. 0.24 ± 0.54, p = 0.029), the ratio of OLGA-stage 0-II/III, IV (13/8 vs. 55/11, p = 0.038) were significantly higher for the gastric cancer group. Multivariate analysis also showed the highest odds ratio (6.26, 95% confidence interval or CI, 1.28-30.60, p = 0.023) for IM at the greater curvature of the corpus.


CONCLUSIONS
Severe endoscopical atrophy, OLGA staging, histological atrophy at the antrum, inflammation, and particularly IM at the corpus, were identified as risk factors for gastric cancer development following H. pylori eradication. Therefore, eradication should be performed before these predictors develop.
Department of Gastroenterology, Faculty of Medicine, Oita University , Hasama-machi, Oita, 879 5593 , Japan.
Masaaki
M
Kodama
Kazunari
K
Murakami
Tadayoshi
T
Okimoto
Hisanori
H
Abe
Ryugo
R
Sato
Ryo
R
Ogawa
Kazuhiro
K
Mizukami
Seiji
S
Shiota
Yoshifumi
Y
Nakagawa
Wataru
W
Soma
Tsuyoshi
T
Arita
Toshio
T
Fujioka
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001284:Atrophy / Q000382:microbiology / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology / Q000473:pathology*; D005756:Gastritis / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000473:pathology* / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008679:Metaplasia / Q000382:microbiology / Q000473:pathology; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000382:microbiology* / Q000473:pathology*
D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors